Ironwood Pharma's (IRWD) Linzess Sales Missed Estimates; Leerink Partners Reiterates Market Perform

Go back to Ironwood Pharma's (IRWD) Linzess Sales Missed Estimates; Leerink Partners Reiterates Market Perform

Leerink Affirms Ironwood Pharma (IRWD) at 'Market Perform'; No Catalyst Seen in Next 12 - 18 Months

November 4, 2015 9:09 AM EST

Leerink affirms Ironwood Pharma (Nasdaq: IRWD) with a Market Perform rating and $12 price target following Q3 results issued Tuesday night.

Analyst Jason Gerberry commented, IRWD reported 3Q Linzess sales of ~$117 million coming in modestly below our est. of ~$121 million. The miss was modest, and we dont... More

Ironwood Pharma (IRWD) Misses Q3 EPS by 5c

November 3, 2015 4:23 PM EST

Ironwood Pharma (NASDAQ: IRWD) reported Q3 EPS of ($0.25), $0.05 worse than the analyst estimate of ($0.20). Revenue for the quarter came in at $39.6 million versus the consensus estimate of $41.76 million.

For earnings history and earnings-related data on Ironwood Pharma (IRWD) click here.

... More

Trading Radar for 11/3: Groupon (GRPN), Mosaic (MOS), Kellogg (K), Herbalife (HLF), Zillow (Z) Report

November 2, 2015 2:23 PM EST

The Trading Radar highlights key earnings and economic announcements for the next trading session:

Before Markets Open:
Earnings:

1-800-FLOWERS.com (Nasdaq: FLWS) - consensus loss $0.26
ALLETE, Inc. (NYSE: ALE) - consensus EPS $1.00
AMAG Pharma (Nasdaq: AMAG) - consensus EPS $1.21
ANI Pharma (Nasdaq: ANIP) - consensus EPS $0.63
ARIAD Pharma0 (Nasdaq: ARIA) - consensus loss $0.23
Aircastle Limited (NYSE: AYR) - consensus EPS... More